Apple Watch Wins Major Patent Battle Against AliveCor

Related Products We may receive commission on purchases made using these links

Watch Series 11 [GPS 42mm] Smartwatch with Rose Gold Aluminum Case with Light Blush Sport Band - S/M. Sleep Score, Fitness Tracker, Health Monitoring, Always-On Display, Water Resistant

4.8

$299.00 on Amazon

Watch Series 11 [GPS 46mm] Smartwatch with Jet Black Aluminum Case with Black Sport Band - M/L. Sleep Score, Fitness Tracker, Health Monitoring, Always-On Display, Water Resistant

4.8

$329.00 on Amazon

Watch Series 11 [GPS 42mm] Smartwatch with Jet Black Aluminum Case with Black Sport Band - S/M. Sleep Score, Fitness Tracker, Health Monitoring, Always-On Display, Water Resistant

4.8

$299.00 on Amazon

Reviewed by: Y. Garcia

The Apple Watch just dodged another legal bullet. In a major victory for the tech giant, the U.S. Court of Appeals for the Federal Circuit on March 7, 2025, confirmed that AliveCor's heart monitoring patents are invalid, effectively ending a years-long dispute that could have resulted in an Apple Watch import ban. This latest ruling adds another chapter to the ongoing saga between tech giants and smaller companies fighting over wearable health technology patents, according to 9to5Mac.

The battle between Apple and AliveCor has been brewing since 2021, when the health technology company first challenged Apple's heart rate monitoring features. What started as a patent infringement case quickly escalated into a complex legal web involving multiple government agencies and courts. MacRumors reports that AliveCor initially sought a complete import ban on Apple Watches, which could have severely disrupted Apple's wearable business in the United States — demonstrating just how much was riding on this legal outcome.

The patent battle that almost changed everything

Let's break it down. Back in 2021, AliveCor took their grievances to the International Trade Commission, claiming Apple had violated three of their patents related to heart rate monitoring technology, as detailed by Reuters. These weren't just any patents — they covered technology found in AliveCor's KardiaBand, an Apple Watch accessory designed to monitor heart rates, detect irregularities, and perform electrocardiograms to identify conditions like atrial fibrillation.

Here's what made this case particularly compelling: AliveCor's initial momentum suggested Apple might face serious consequences. In June 2022, the ITC reached a preliminary finding that Apple had indeed violated the company's patented technology, according to 9to5Mac. This preliminary victory positioned AliveCor as a potential David capable of bringing down the tech Goliath through patent enforcement.

But Apple wasn't about to roll over. The company launched a sophisticated two-pronged defense strategy that's becoming increasingly common in patent disputes: appealing the ITC ruling while simultaneously challenging the validity of AliveCor's patents at the Patent Trial and Appeal Board. This approach recognizes a fundamental legal reality — if you can't win on infringement, eliminate the patents entirely.

Apple's strategic gamble paid off spectacularly. In December 2022, the PTAB ruled that AliveCor's three patents were unpatentable, essentially determining that the patent claims were either too obvious or too generic, Mass Device reports. This created a fascinating legal paradox where the ITC had found infringement, but only if the patents were actually valid — which they apparently weren't.

The whole dispute remained suspended in legal uncertainty while appeals played out. The ITC had recommended a limited exclusion order and cease-and-desist for the Apple Watch, but those orders were suspended while the Federal Circuit considered the appeals, as MacRumors notes. During this period, Apple continued selling Apple Watches while both companies awaited the final judicial verdict.

Why this ruling matters for Apple's ecosystem

Bottom line: this victory gives Apple significant breathing room to continue developing health features for the Apple Watch without worrying about AliveCor's patent claims. The Federal Circuit's decision doesn't just dismiss the immediate case — it validates Apple's approach to defending its technology through patent challenges, according to MacRumors.

Apple thanked the court for its work and confirmed it will continue developing new Apple Watch health features, as reported by MacRumors. This commitment signals Apple's confidence that its patent defense strategy can protect future health innovations from similar challenges.

What makes this victory particularly strategic is how it contrasts with Apple's ongoing Masimo dispute. While Apple successfully defended against AliveCor's patents through invalidation, the company has struggled with different defensive approaches against medical device maker Masimo. Apple Watch models in the U.S. are still subject to an import ban related to blood oxygen sensing technology, MacRumors notes, forcing Apple to disable this feature in watches sold domestically. The difference demonstrates that patent challenges in health tech require tailored defensive strategies — what works against one challenger may not succeed against another.

The AliveCor ruling effectively removes a significant legal cloud that had been hanging over Apple's wearable strategy. Health monitoring has become a cornerstone feature driving Apple Watch adoption, so any threat to those capabilities could have seriously impacted the product's market position and future development roadmap.

What AliveCor's response tells us about the bigger picture

AliveCor's reaction to the ruling reveals the broader competitive tensions between established tech giants and smaller innovation companies. The company expressed disappointment with the court's decision but emphasized that the ruling doesn't affect their business operations or innovation capabilities, according to 9to5Mac. More significantly, AliveCor positioned this legal battle within a larger narrative about market power and innovation protection.

AliveCor framed their legal battle as representing "every small company and future innovation at risk of being suppressed by a Goliath." This David-versus-Goliath messaging taps into widespread concerns about how large tech companies leverage their resources to outmaneuver smaller competitors through legal channels rather than just market competition.

This competitive dynamic extends beyond patent law into antitrust territory. AliveCor has indicated they'll continue exploring legal options, including potential appeals, Mass Device reports. The company also noted that their separate antitrust lawsuit against Apple was dismissed last year and was rejected on appeal on January 8, 2026.

Understanding the distinction between these legal theories is crucial: the patent dispute centered on whether Apple violated AliveCor's intellectual property rights, while the antitrust case involved broader allegations that Apple illegally monopolized the heart rate monitoring app market for Apple Watch, Reuters reported. The antitrust claims focused on AliveCor's allegations that Apple's software updates deliberately broke compatibility with third-party heart monitoring apps, representing a fundamentally different competitive challenge than patent infringement.

Where Apple's legal strategy goes from here

This victory demonstrates Apple's increasingly sophisticated approach to patent defense, particularly in the health technology space where the stakes are highest. The company's success in invalidating AliveCor's patents through the PTAB process shows how tech giants can leverage existing patent law mechanisms to defend against infringement claims, as detailed by Law360.

The Federal Circuit's ruling that AliveCor's patents were obvious based on prior research and existing technology carries broader implications for health tech innovation policy, Mass Device notes. When patents are invalidated for obviousness, it suggests the technology wasn't sufficiently novel to deserve patent protection in the first place. This creates a precedent that could make it harder for companies to secure broad patents on basic health monitoring functions, potentially benefiting the entire industry by preventing overly expansive patent claims that stifle innovation.

The court's rejection of AliveCor's arguments that Apple's evidence was flawed — affirming that substantial prior art already existed for the disputed technology — reinforces the importance of thorough prior art research in patent challenges. This legal foundation could encourage more companies to challenge questionable patents rather than accepting potentially invalid intellectual property claims.

However, Apple's ongoing struggles with Masimo serve as a crucial reminder that patent challenges in health technology remain unpredictable and highly context-dependent. While the AliveCor victory removes one significant threat to Apple Watch imports, Reuters confirms that other patent holders may still pose challenges to Apple's wearable ambitions.

The key takeaway is that Apple's legal strategy appears to be evolving toward proactive patent challenge rather than purely defensive positioning. Instead of simply defending against infringement claims, the company is systematically challenging questionable patents through the PTAB process. This approach requires significant legal resources but can completely eliminate patent threats rather than merely defending against them. For a company with Apple's legal capabilities and strategic importance in health tech, this aggressive defensive posture represents a sustainable long-term approach to patent risk management.

What this means for the broader wearable health tech market is equally significant. Apple's success in clearing questionable patents could encourage more innovation by removing potential legal barriers, while simultaneously demonstrating the substantial resources required to challenge patent claims — resources that smaller innovators might not possess. This dynamic is likely to continue shaping how health tech patents are prosecuted, defended, and ultimately validated in an increasingly competitive marketplace.